Skip to content

CJC-1295: Albumin Binding, Human Hormone Studies and the No-DAC Distinction

Human studies of long-acting CJC-1295 measured growth-hormone and IGF-I responses. They do not establish equivalent exposure for no-DAC products or demonstrate general anti-aging, muscle-building or fat-loss benefits.

By Peptide Mag Editorial. Updated . Source and review policy.

Identity that matters
Albumin-binding CJC-1295 is not interchangeable with no-DAC labeling
Human outcomes examined
GH and IGF-I concentrations, pharmacokinetics and overnight secretion
Clinical boundary
A hormonal response is not a demonstrated long-term health benefit

The Simple Truth

Why this exists and what it’s supposed to do.

CJC-1295 exists because the body's natural growth hormone signal lasts minutes.

Your pituitary releases growth hormone in pulses when the hypothalamus signals it with GHRH. Natural GHRH is cleared almost immediately.

What it is supposed to do: raise your own growth hormone output over days rather than minutes, so people use it hoping for better recovery, sleep, body composition and the general effects attributed to growth hormone — without injecting growth hormone itself.

It does reliably raise hormone levels in human studies. Whether raised levels deliver the outcomes people want is a separate question, and much weaker.

Identify the molecule before interpreting the half-life

CJC-1295 belongs to growth hormone-releasing hormone analogue research. Its defining long-acting design includes an albumin-binding modification; the duration is not a property that can be assigned to every product with CJC in its name. The original development paper describes the modified molecule and albumin association using laboratory and rat experiments.

A product labeled CJC-1295 no DAC or modified GRF(1-29) needs a separate identity specification. Without the albumin-binding feature, it is not the same intervention as the long-acting study drug. A sequence, terminal modifications and conjugation details are more informative than shorthand. The human long-duration results below must not be copied onto an unspecified no-DAC preparation.

What the randomized adult studies measured

The 2006 report describes two placebo-controlled, double-blind, ascending-dose studies lasting 28 and 49 days in healthy adults aged 21–61. Subcutaneous administration of the long-acting analogue produced sustained increases in GH and IGF-I. The estimated elimination half-life ranged from 5.8 to 8.1 days.

Those are exposure and endocrine findings. The trials do not supply a controlled demonstration of better athletic performance, longer life or a general body-composition benefit. A study can establish that a compound reaches its biological target without establishing that raising the measured hormone is desirable for a different person or purpose.

Preserved pulses do not mean unchanged secretion

A separate 2006 investigation sampled healthy men's blood overnight before and one week after administration. Pulsatile secretion persisted, while trough and average GH and IGF-I increased. The reported pulse frequency and magnitude were not significantly changed.

This distinction matters when a claim says the drug simply restores natural pulses. Pulse timing, baseline secretion and total exposure are different measurements. Preserved pulsatility alone cannot establish an optimal endocrine pattern, protection from adverse effects or a benefit from adding another secretagogue.

Safety and regulatory context are separate evidence

The early adult report did not record serious adverse reactions in its study setting. That limited observation is not a guarantee about prolonged exposure, other illnesses or combinations. FDA's compounding safety discussion separately identifies concerns involving CJC-1295, including reported serious cardiovascular reactions and limited clinical data.

A paper describing experimental administration is not a marketing authorization. Regulatory statements should identify the exact finished product, jurisdiction and current document. Neither a research label nor a supplier's analytical certificate converts these short endocrine studies into a clinical approval.

What this evidence says about CJC/ipamorelin blends

The cited CJC studies did not test a commercial CJC/ipamorelin blend. A second receptor pathway is a hypothesis to investigate, not proof of superior outcomes or a known combined safety profile. See the CJC/ipamorelin evidence guide for the additional comparisons a combination would require.

The identity question comes first there too: a blend containing a no-DAC material cannot borrow the exposure profile of albumin-binding CJC-1295. Even a correctly identified long-acting component would not establish the stability, measured content or biological behavior of a finished mixture.

Questions a stronger study would answer

Useful follow-up evidence would specify the material and route, prespecify a meaningful clinical outcome, use an appropriate comparator and assess harms over an adequate period. It should distinguish hormone changes from changes in symptoms, function or disease risk. The number analyzed and reasons for withdrawal are part of that assessment.

This guide therefore offers neither a cycle nor a personal dosing schedule. Its practical purpose is to help a reader recognize which version of the molecule a paper studied, what the investigators measured and where an attractive benefit claim begins to exceed the result.

Sources and further reading

  1. Jetté et al., 2005: albumin-bioconjugate development
  2. Teichman et al., 2006: randomized adult exposure studies
  3. Ionescu and Frohman, 2006: overnight GH secretion
  4. FDA: safety concerns for certain compounding substances

Continue reading